drugset / Trial / NCT00348192

SB-742457 And Donepezil In Alzheimer's Disease

NCT00348192

Phase 2 Completed 200 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's Disease.

Timeline

Start
2006-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 10 mg
Subject intepirdine Small molecule 35 mg

Indications